Adherex Technologies Inc. FENC
- Market cap
- $372.4M
- P/E
- 0.0×
Follow FENC
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.09 | 1.94 | 5.33 | 3.26 | 4.65 | 3.82 | 4.11 | 6.30 | 3.96 | 4.68 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 3.06 | 13.95 | 14.99 | 7.65 | 10.67 | 10.08 | 10.38 | 11.92 | 11.49 | 9.92 |
High Price
|
|||
| 3 | 3 | 3 | 4 | 9 | 10 | 36 | 29 | 32 | 35 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| — | — | — | — | 0 | — | 2 | 21 | 48 | 45 |
Revenue
|
|||
| — | — | — | — | 100.00% | — | 94.40% | 94.08% | 93.30% | 91.57% |
Gross Margin
|
|||
| (3) | (7) | (10) | (13) | (18) | (17) | (24) | (16) | 0 | (10) |
EBT
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | (10,652.35%) | 0.00% | (1,544.30%) | (75.50%) | (0.15%) | (21.58%) |
EBT Margin
|
|||
| (3) | (7) | (10) | (13) | (18) | (17) | (24) | (16) | 0 | (10) |
Net Income
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.06 | 0.80 | 1.74 | 1.56 |
Revenue/Sh
|
|||
| (0.22) | (0.47) | (0.50) | (0.64) | (0.76) | (0.67) | (0.90) | (0.60) | (0.02) | (0.35) |
Earnings/Sh
|
|||
| (0.17) | (0.24) | (0.41) | (0.46) | (0.66) | (0.55) | (0.69) | (0.65) | 0.99 | (0.44) |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (0.17) | (0.24) | (0.41) | (0.46) | (0.66) | (0.55) | (0.69) | (0.65) | 0.99 | (0.44) |
Free CF/Sh
|
|||
| 0.28 | 1.78 | 1.13 | 0.60 | 1.23 | 0.61 | (0.10) | (0.44) | (0.22) | 1.24 |
Book Value/Sh
|
|||
| 13 | 15 | 19 | 20 | 24 | 26 | 26 | 27 | 27 | 29 |
Shares
|
|||
| — | — | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 0.00 | — | 0.00 | 13.90 | 3.63 | 4.93 |
PS Ratio
|
|||
| — | — | — | — | 6.07 | — | 0.00 | 0.00 | 0.00 | 6.20 |
PB Ratio
|
|||
| — | — | — | — | 0.00 | — | 0.00 | 14.68 | 3.45 | 4.52 |
EV/Sales
|
|||
| — | — | — | — | (9.38) | — | (14.70) | (18.20) | 6.09 | (16.16) |
EV/FCF
|
|||
| (2) | (4) | (8) | (9) | (16) | (14) | (18) | (17) | 27 | (12) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| (2) | (4) | (8) | (9) | (16) | (14) | (18) | (17) | 27 | (12) |
FCF
|
|||
| 4 | 27 | 21 | 12 | 29 | 21 | 22 | 19 | 37 | 57 |
Working Cap'
|
|||
| — | — | — | — | — | 5 | 25 | 30 | 18 | — |
Total Debt
|
|||
| (4) | (28) | (23) | (14) | (30) | (16) | 1 | 16 | (9) | (37) |
Net Debt
|
|||
| 4 | 27 | 21 | 12 | 29 | 16 | (3) | (12) | (6) | 35 |
Sh' Equity
|
|||
| (111.76%) | (43.53%) | (38.51%) | (68.88%) | (79.49%) | (64.45%) | (96.10%) | (59.64%) | (1.21%) | (16.87%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (165.56%) | 0.00% | 0.00% |
ROIC
|
|||
| (135.45%) | (46.47%) | (41.14%) | (76.99%) | (88.46%) | (77.36%) | (359.22%) | 226.13% | 4.98% | (65.82%) |
ROE
|
|||
Adherex Technologies Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CCCC C4 Therapeutics, Inc. | $372.8M | 0.0× | Compare |
| CABA Cabaletta Bio, Inc. | $373.0M | 0.0× | Compare |
| AGEN Agenus Inc. | $375.3M | 3.2× | Compare |
| ARTV Artiva Biotherapeutics, Inc. | $366.2M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OBIO Orchestra BioMed Holdings, Inc. | $366.0M | 0.0× | Compare |
| RZLT Rezolute, Inc. | $379.4M | 0.0× | Compare |
| SRZN Surrozen, Inc. | $386.6M | 0.0× | Compare |
| TTRX Turn Therapeutics Inc. | $395.0M | 0.0× | Compare |
Adherex Technologies Inc. (FENC) key facts
- Adherex Technologies Inc. (FENC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Adherex Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was CAD 44.6 million, down 6.09% from fiscal 2024.
- As of September 25, 2026, FENC traded at $10.61, a market capitalization of $372.4 million.
- Return on equity was −65.8% and debt-to-equity 0.00.
Adherex Technologies Inc. (FENC) Latest News
14 Aug
Analysts raised PEDMARK views, lifting fair value for Fennec Pharmaceuticals (FENC) stock. Analyst upgrades on PEDMARK produce higher fair value targets that may influence near-term investor sentiment for Fennec.
11 Aug
Fennec Pharmaceuticals Inc (FENC) reported record sales during its Q2 2026 earnings call. Record sales signal strong revenue growth that can materially lift valuation and market position.
Adherex Technologies Inc. presented Q2 financial results, operational updates and outlook during its earnings call. Quarterly earnings provide updated financial metrics and guidance that can influence near-term stock movement.
Fennec Pharmaceuticals reported second quarter 2026 financial results and provided a business update. Quarterly results and updates typically produce moderate short-term effects on financial performance and investor views.
23 May
Adherex Technologies targets larger AYA market with PEDMARK following record quarter. PEDMARK expansion into larger AYA segment after record quarter signals major growth trajectory shift.
22 May
Fennec Pharmaceuticals presented new research data supporting expanded use of Pedmark at the ASCO Annual Meeting. Supportive research presentation at major oncology conference can lift product visibility and near-term sentiment without immediate revenue impact.
21 May
Fennec Pharmaceuticals announced new research supporting integration and use of PEDMARK® at the 2026 ASCO Annual Meeting. New research supporting PEDMARK integration at major oncology conference boosts product visibility and adoption prospects.
14 May
Fennec Pharmaceuticals Inc. (FENC) delivered record sales surge in Q1 2026 earnings call, highlighting strong revenue growth and positive financial momentum. Record sales surge fundamentally enhances FENC's competitive position and long-term prospects.
Fennec Pharmaceuticals (FENC) shares rose after earnings and revenue exceeded forecasts. Earnings and revenue beats triggered share price gains, enhancing investor sentiment and financial outlook.
Fennec Pharmaceuticals (FENC) shares rose 12.6% in U.S. pre-market trading after Q1 earnings revealed Pedmark sales surging 73%. 73% Pedmark sales growth in Q1 drove 12.6% pre-market stock surge, significantly enhancing financial performance and investor sentiment.
Adherex Technologies Inc. (FENC) beat Q1 earnings and revenue estimates. Beating Q1 earnings and revenue estimates boosts investor sentiment and stock performance significantly.
Fennec Pharmaceuticals reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates significantly impact investor sentiment and market performance for a pharmaceutical company.
Fennec Pharmaceuticals Inc. (FENC), formerly Adherex Technologies Inc., released its Q1 2026 earnings call summary highlighting financial performance and updates. Q1 2026 earnings summary directly impacts financial reporting and investor perceptions of near-term performance.
Adherex Technologies Inc. (FENC) Q1 earnings call highlights quarterly financial results, operational updates, and forward guidance. Q1 earnings highlights address financial performance and strategic outlook with moderate influence on Adherex Technologies' trajectory.
21 Apr
Fennec Pharmaceuticals announces acceptance of its abstracts for presentation at the 2026 ASCO Annual Meeting. Abstract acceptance at ASCO boosts visibility for Fennec's oncology-related research and may positively influence investor sentiment ahead of the 2026 meeting.
25 Mar
Fennec Pharmaceuticals Inc. released Q4 2025 earnings call summary detailing financial results, operational updates, and forward guidance. Q4 2025 earnings call summary reveals key financial performance and strategic outlook directly influencing FENC's trajectory and investor sentiment.
24 Mar
Fennec Pharmaceuticals Inc. (FENC) reported record sales in Q4 2025 earnings call, highlighting strategic initiatives amid strong financial performance. Record sales and strategic highlights signal major positive shifts in financials and market positioning for FENC.
Adherex Technologies Inc. (FENC) released Q4 earnings call highlights covering financial results, operational updates, and forward-looking guidance. Q4 earnings call highlights disclose financial performance and strategic plans likely to significantly sway investor sentiment and stock trajectory.
Fennec Pharmaceuticals announced fourth quarter and full-year 2025 financial results alongside a business update. Quarterly and annual earnings reports with business updates directly drive stock volatility and long-term investor outlook.
Adherex Technologies Inc. (FENC) reported a Q4 loss and missed revenue estimates. Q4 loss and missed revenue estimates signal weaker financial results, moderately affecting stock price and investor confidence.
17 Mar
B. Riley reaffirms Buy rating on Fennec Pharmaceuticals (FENC) with US$16.00 price target following Cipla settlement. Analyst reaffirmation of Buy rating post-Cipla settlement moderately boosts investor sentiment and short-term market performance.
16 Mar
Fennec Pharmaceuticals announces settlement agreement resolving PEDMARK patent litigation involving Adherex Technologies Inc. (FENC). Settlement removes patent litigation uncertainty for PEDMARK, a key product, positively impacting FENC's commercialization and market trajectory.
15 Mar
A water giant with $7 billion in revenue invested $7.5 million in Adherex Technologies Inc. (FENC), causing shares to surge this year. $7.5 million investment from a $7 billion revenue water giant represents a major strategic endorsement likely to enhance FENC's market position and performance.
Adherex Technologies Inc. (FENC) payments stock plunges 30% despite reporting $4 billion in revenue, attracting a $6 million bullish bet. $4 billion revenue amid 30% stock drop and $6 million bet signals major shifts in investor sentiment and performance trajectory.
4 Mar
Fennec Pharmaceuticals announces clinical research collaboration with Tampa General Hospital Cancer Institute. Clinical research collaboration with a major cancer institute supports Fennec's oncology pipeline and may moderately boost investor sentiment.
2 Mar
Adherex Technologies Inc. (FENC) earnings expected to grow ahead of Q4 release, with key factors to watch including analyst projections and historical performance. Expected earnings growth previews potential moderate boost to financial performance and investor sentiment.
20 Feb
Fennec Pharmaceuticals presented real-world data supporting Pedmark's use in treating adults with head and neck cancers, demonstrating efficacy in preventing cisplatin-induced hearing loss. Real-world data expands Pedmark's potential market beyond pediatrics to adults, boosting revenue prospects and investor sentiment.
Fennec Pharmaceuticals presented real-world data supporting PEDMARK® integration and clinical use in treating adults with head and neck cancers. Real-world data validates PEDMARK for adult head and neck cancer treatment, expanding market potential and positively influencing investor sentiment.
6 Jan
Insider buying activity at Fennec Pharmaceuticals has been noted, with multiple executives purchasing shares, signaling confidence in the company's future. This trend is often interpreted as a positive indicator for investors, suggesting that those with inside knowledge believe the stock is undervalued or that the company is on a promising trajectory. Insider purchases can indicate confidence in the company's future performance, potentially influencing market sentiment.
26 Dec
Southpoint Capital Advisors LLC has increased its holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) to 5.1 million shares, representing a 10.1% ownership stake. This move reflects Southpoint's confidence in Fennec's potential, particularly following the recent FDA approval of its lead product, Pedmark, for preventing hearing loss in pediatric patients undergoing cisplatin chemotherapy. The approval is expected to significantly enhance Fennec's market position and financial outlook. The FDA approval of Pedmark is a significant strategic development that could greatly influence Fennec's future performance and investor sentiment.